Takeda Pharmaceutical anunció el jueves 18 de octubre que la Comisión de Comercio Justo de Japón ha dado luz verde a su adquisición de Shire por US$62,000 millones de dólares, lo que acercó a la firma japonesa a cerrar un acuerdo que lo convertirá en uno de los 10 principales fabricantes de medicamentos del mundo. El acuerdo, que será la mayor compra en el extranjero por parte de una empresa japonesa, ya ha recibido la autorización incondicional de los reguladores en los Estados Unidos, Brasil y China.
Featured News
Butterball Moves to End Turkey Antitrust Litigation With $34M Pact
Aug 23, 2026 by
CPI
Uber’s California Racketeering Case Against Lawyers, Doctors Moves Forward
Aug 23, 2026 by
CPI
Epic Challenges Apple’s Compliance With Brazil App Store Antitrust Settlement
Aug 23, 2026 by
CPI
EU Ends Pratt & Whitney Canada Antitrust Probe After Contract Changes
Aug 23, 2026 by
CPI
Paramount, California to Meet Monday on Antitrust Settlement
Aug 23, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Antipasto
Aug 24, 2026 by
CPI
“Anti-Monopoly” Antitrust Enforcement: Lessons Learned from the Biden Administration
Aug 24, 2026 by
Diana L. Moss
FTC v. Meta: The Importance of Quantitative Evidence in Antitrust
Aug 24, 2026 by
Dennis Carlton, John A. List, Allan Shampine, Hal Sider & Theresa Sullivan
Competitor Information Exchanges: Reducing Market Uncertainty Is What Matters, Not Level Of Detail
Aug 24, 2026 by
Kasia Czapracka, Assimakis Komninos, James Killick & Nina Frie
When Politics Meets Merger Control: 10 Transatlantic Takeaways
Aug 24, 2026 by
Rachel Brandenburger